Raltegravir plus Ritonavir-Boosted Darunavir

ACTG 5262 Trial
**Study Design: ACTG 5262**

- **Background**: Open-label, single-arm, phase 2 study evaluating the efficacy of a NRTI-sparing regimen consisting of boosted darunavir plus raltegravir

- **Inclusion Criteria** (n = 112)
  - Age ≥ 18 years
  - Antiretroviral-naïve
  - HIV RNA ≥ 5000 copies/mL
  - More than one darunavir resistance-associated mutation (RAM) or known major integrase RAM

- **Treatment Arm**
  - Darunavir 800 mg QD + Ritonavir 100 mg QD + Raltegravir 400 mg BID

Raltegravir plus Ritonavir-Boosted Darunavir
ACTG 5262 Trial: Result

Week 24 and Week 48: Virologic Efficacy

Raltegravir plus Ritonavir-Boosted Darunavir
ACTG 5262 Trial: Result

Week 24 and Week 48: Virologic Failure (Intent-to-Treat Analysis)

Virologic failure associated with baseline HIV RNA >100,000 copies/mL and lower CD4 count

Raltegravir plus Ritonavir-Boosted Darunavir

ACTG 5262: Result

Virologic Failure, by Baseline CD4 Count

Conclusion: “DRV/r + RAL was effective and well tolerated in most patients, but virological failure and integrase resistance were common, particularly in patients with baseline viral load more than 100,000 copies/ml.”

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.